Werner syndrome

Last updated
Werner syndrome (progeria)
Autorecessive.svg
Werner syndrome has an autosomal recessive pattern of inheritance.
Specialty Endocrinology   OOjs UI icon edit-ltr-progressive.svg

Werner syndrome (WS) or Werner's syndrome, also known as "adult progeria", [1] is a rare, autosomal recessive disorder [2] which is characterized by the appearance of premature aging. [3]

Contents

Werner syndrome is named after the German scientist Otto Werner. [4] He identified the syndrome in four siblings observed with premature aging, which he explored as the subject of his dissertation of 1904. [5]

It has a global incidence rate of less than 1 in 100,000 live births [6] (although incidence in Japan and Sardinia is higher, affecting 1 in 20,000–40,000 and 1 in 50,000, respectively). [7] [8] 1,300 cases had been reported as of 2006. [9] Affected individuals typically grow and develop normally until puberty; the mean age of diagnosis is twenty-four, often realized when the adolescent growth spurt is not observed. [10] The youngest person diagnosed was six years old. [11] The median and mean ages of death are 47–48 and 54 years, respectively. [12] The main causes of death are cardiovascular disease and cancer. [9] [10]

Presentation

Werner syndrome patients exhibit growth retardation, short stature, premature graying of hair, alopecia (hair loss), wrinkling, prematurely aged faces with beaked noses, skin atrophy (wasting away) with scleroderma-like lesions, lipodystrophy (loss of fat tissues), abnormal fat deposition leading to thin legs and arms, and severe ulcerations around the Achilles tendon and malleoli (around ankles). Other symptoms include change in voice (weak, hoarse, high-pitched), atrophy of gonads leading to reduced fertility, bilateral cataracts (clouding of lens), premature arteriosclerosis (thickening and loss of elasticity of arteries), calcinosis (calcium deposits in blood vessels), atherosclerosis (blockage of blood vessels), type 2 diabetes, osteoporosis (loss of bone mass), telangiectasia, and malignancies. [6] [9] The prevalence of rare cancers, such as meningiomas, are increased in individuals with Werner syndrome. [13]

Gene expression

Gene transcription changes found in WS cells are strikingly similar to those observed in normal aging. [14] At the level of gene expression, WRN protein deficiency causes changes in the pattern of gene expression that markedly resemble those of normal old age. [15]

Diagnosis and clinical symptoms

The mutation in the WRN gene that causes Werner syndrome is autosomal and recessive, meaning that affected people must inherit a copy of the gene from each parent. Patients display rapid premature aging beginning in young adulthood, usually in their early twenties. [16] Diagnosis is based on six cardinal symptoms: premature graying of the hair or hair loss, presence of bilateral cataracts, atrophied or tight skin, soft tissue calcification, sharp facial features, and an abnormal, high-pitched voice. [17] Patients are generally short-statured due to absence of the adolescent growth spurt. Patients also display decreased fertility. [18] The most common symptom of the six is premature graying and loss of hair. This is also generally the earliest observed symptom, with hair loss occurring first on the scalp and the eyebrows. [18]

Werner syndrome patients often have skin that appears shiny and tight, and may also be thin or hardened. [16] [18] This is due to atrophy of the subcutaneous tissue and dermal fibrosis. [18] Over time, the characteristic facial features may be more apparent due to these skin conditions. Other associated skin conditions include ulcers, [18] which are very difficult to treat in Werner syndrome patients, and are caused in part by decreased potential of skin cells for replication. [19]

WS cataracts are distinctly different from those of normal aging. They are associated with problems in the lens posterior cortex and subcapsular regions. These cataracts are generally treatable with cataract surgery, which should restore normal vision. [18]

Symptoms become apparent in the late teens and early twenties and continue to progress. Most patients live to about fifty years of age. The most common causes of death for people are associated diseases and complications, especially atherosclerosis and cancer. [16]

Associated diseases

Werner syndrome patients are at increased risk for several other diseases, many associated with aging. Atherosclerosis, the thickening of artery walls due to cholesterol buildup, is one common complication. [17] While normal atherosclerosis generally involves the major arteries, smaller arterioles are more likely to be affected. [20] It is possible nervous system disorders are associated. Brain atrophy is present in 40% of patients. [19] [17] Osteoporosis, the loss of bone mineral density common in post-menopausal women, is another common symptom. In contrast with the normal population, the rate of osteoporosis is especially high for male patients. [19] Diabetes mellitus is another common accompaniment. [17] Skin ulcers occur in about 75% of patients – and can be difficult to treat. If skin ulcers become badly infected or develop gangrene, they often require amputation. Unlike most other related diseases and complications, these ulcers are not associated with normal aging. [19]

Patients are also at an increased risk of cancer, especially malignant melanoma. [19] Soft-tissue sarcomas are the most common cancer types. [18] Other types of skin cancer, other epithelial cancers such as thyroid and liver cancers, MDS (myelodysplastic syndrome), and MFH (malignant fibrous histiocytoma) are also prevalent among. [19] Mutations in the WRN gene, especially single-nucleotide polymorphisms (SNPs), are associated with many of the cancers and other associated diseases. WRN SNPs correlate with cancers such as sarcomas and non-Hodgkin lymphomas, as well as diabetes and cardiovascular problems including atherosclerosis. [21]

Causes

Approximately 90% of individuals presenting Werner syndrome have any of a range of mutations in the gene, WRN , the only gene currently attributed to cause Werner syndrome. [11] [12] WRN, which lies on chromosome 8 in humans, [22] encodes the WRNp protein, a 1432 amino acid protein with a central domain resembling members of the RecQ helicases. RecQ helicases are a special type of helicase that function at unique times during DNA repair of doubled stranded breaks, which are a form of DNA damage that results in a break of both strands of DNA. Thus, RecQ helicases are important for maintaining DNA stability, and loss of function of these helicases has important implications in the development of Werner syndrome. [23] In addition to the central domain, there are three exonuclease domains at the N-terminus and a Helicase and Ribonuclease D C-terminal (HRDC) domain at the C-terminus. [24]

When functioning normally, the WRN gene and its associated protein (WRNp) are important for maintaining genome stability. [20] WRNp is active in unwinding DNA, a step necessary in DNA repair and DNA replication. [3] [7] Specifically, it has an important role in responding to replication malfunctions, particularly double-stranded breaks, and stalled replication machinery. [20] WRNp may reactivate replication by preventing unwanted recombination processes from occurring or by promoting recombination, depending on the type of DNA damage. In addition, WRNp physically interacts with or binds to several other proteins that are involved in processing DNA. [25] For example, when WRNp binds to RPA, its helicase activity is stimulated. WRNp also physically interacts with p53, a tumor suppressor gene that stops the formation of tumors and the progression of cancers, [26] which inhibits the exonuclease activity of the WRNp. [27] Since WRNp's function depends on DNA, it is only functional when localized to the nucleus.[ citation needed ]

Surprisingly, complete loss of WRN helicase activity does not cause clinical Werner syndrome. [28]

DNA repair processes

The finding that WRN protein interacts with DNA-PKcs and the Ku protein complex, combined with evidence that WRN deficient cells produce extensive deletions at sites of joining of non-homologous DNA ends, suggests a role for WRN protein in the DNA repair process of non-homologous end joining (NHEJ). [29] WRN protein also physically interacts with the major NHEJ factor X4L4 (XRCC4-DNA ligase 4 complex). [30] X4L4 stimulates WRN exonuclease activity that likely facilitates DNA end processing prior to final ligation by X4L4. [30]

WRN protein appears to play a role in resolving recombination intermediate structures during homologous recombinational repair (HRR) of DNA double-strand breaks. [29]

WRN protein participates in a complex with RAD51, RAD54, RAD54B and ATR proteins in carrying out the recombination step during inter-strand DNA cross-link repair. [31]

Evidence was presented that WRN protein plays a direct role in the repair of methylation induced DNA damage. This process likely involves the helicase and exonuclease activities of WRN protein that operate together with DNA polymerase beta in long patch base excision repair. [32]

Effects on cell structure and function

Mutations which cause Werner syndrome all occur at the regions of the gene which encode for protein, and not at non-coding regions. [33] There are 35 different known mutations of WRN, which correspond to stop codons, insertions, or deletions that result in a frameshift mutation. [27] These mutations can have a range of effects. They may decrease the stability of the transcribed messenger RNA (mRNA), which increases the rate at which they are degraded. With less mRNA, less is available to be translated into the WRNp protein. Mutations may also lead to the truncation (shortening) of the WRNp protein, leading to the loss of its nuclear localization signal sequence, thus it is no longer transported into the nucleus where it interacts with the DNA. This leads to a reduction in DNA repair. [33] Furthermore, mutated proteins are more likely to be degraded than normal WRNp. [7] Apart from causing defects in DNA repair, its aberrant association with p53 down-regulates the function of p53, leading to a reduction in p53-dependent apoptosis and increasing the survival of these dysfunctional cells. [34] Cells of affected individuals also have reduced lifespan in culture, [35] have more chromosome breaks and translocations [36] and have extensive deletions. [37]

Patients with Werner syndrome lose the RecQ helicase activity in the WRN protein because of the loss of its C-terminus region, but the mechanism by which this happens is unclear. The loss of the helicase activity can have far-reaching consequences in terms of cell stability and mutation. One instance of these consequences involves telomeres. It is thought that the WRN helicase activity is important not only for DNA repair and recombination, but also for maintaining telomere length and stability. Thus, WRN helicase is important for preventing catastrophic telomere loss during DNA replication. [38] In a normal cell, the telomeres (the ends of chromosomes) undergo repeated shortening during the cell cycle, which can prevent the cell from dividing and multiplying. This event can be counteracted by telomerase, an enzyme that extends the ends of the chromosomes by copying the telomeres and synthesizing an identical, but new end that can be added to the existing chromosome. [39] However, patients with Werner syndrome often exhibit accelerated telomere shortening, indicating that there may be a connection between the loss of the WRN helicase activity and telomere and cell instability. While evidence shows that telomere dysfunction is consistent with the premature aging in WS, it has yet to be determined if it is the actual cause of the genomic instability observed in cells and the high rate of cancer in WS patients. [38]

Without the WRN protein, the interwoven pathways of DNA repair and telomere maintenance fail to suppress cancer and the aging symptoms seen in patients with WS. Events such as rapid telomere shortening cause Werner syndrome cells to exhibit low responses to overall cellular stress. In addition to telomere dysfunction, over-expression of oncogenes and oxidation can induce this type of response. High stress causes a synergistic effect, where WS cells become even more sensitive to agents that increase cell stress and agents that damage DNA. As a result, WS cells show a drastic reduction in replicative lifespan and enter into a stage of aging prematurely. The accumulation of these damaged cells due to telomere shortening over many years may be indicative of why Werner syndrome symptoms only appear after an individual is about twenty years old. [40]

Protection of DNA against oxidative damage

WRN protein was found to have a specific role in preventing or repairing DNA damages resulting from chronic oxidative stress, particularly in slowly replicating cells. [41] This finding suggested that WRN may be important in dealing with oxidative DNA damage that underlies normal aging [41] (see DNA damage theory of aging).

Diagnosis

Treatment

A cure for Werner syndrome has not yet been discovered. It is often treated by managing the associated diseases and relieving symptoms to improve quality of life. The skin ulcers that accompany WS can be treated in several ways, depending on the severity. Topical treatments can be used for minor ulcers, but are not effective in preventing new ulcers from occurring. In the most severe cases, surgery may be required to implant a skin graft or amputate a limb if necessary. Diseases commonly associated with Werner syndrome such as diabetes and cancer are treated in generally the same ways as they would be for a non-Werner syndrome individual. A change in diet and exercise can help prevent and control arteriosclerosis, and regular cancer screenings can allow for early detection of cancer. [42]

There is evidence that suggests that the cytokine-suppressive anti-inflammatory drug SB203580 may be a possible therapeutic option for patients with Werner's syndrome. This drug targets the p38 signaling pathway, which may become activated as a result of genomic instability and stalled replication forks that are characteristic mutations in WS. This activation of p38 may play a role in the onset of premature cell aging, skin aging, cataracts, and graying of the hair. The p38 pathway has also been implicated in the inflammatory response that causes atherosclerosis, diabetes, and osteoporosis, all of which are associated with Werner's syndrome. This drug has shown to revert the aged characteristics of young WS cells to those seen in normal, young cells and improve the lifespan of WS cells in vitro. SB203580 is in the clinical trial stages, and the same results have not yet been seen in vivo. [43]

In 2010, vitamin C supplementation was found to reverse the premature aging and several tissue dysfunctions in a genetically modified mouse model of the disease. Vitamin C supplementation also appeared to normalize several age-related molecular markers such as the increased levels of the transcription factor NF-κB. In addition, it decreases activity of genes activated in human Werner syndrome and increases gene activity involved in tissue repair. Supplementation of vitamin C is suspected to be beneficial in the treatment of human Werner syndrome, although there was no evidence of anti-aging activity in nonmutant mice. [44] In general, treatments are available for only the symptoms or complications and not for the disease itself. [45]

History

Otto Werner was the first to observe Werner syndrome in 1904 as a part of his dissertation research. As a German ophthalmologist, Werner described several progeria-like features and juvenile cataracts in many of his patients. He noticed these symptoms particularly in a family with four sequential children who all showed the characteristics of the syndrome at around the same age. He assumed the cause to be genetic, though most of his evidence was clinical. Between 1934 and 1941, two internists from New York, Oppenheimer and Kugel, coined the term "Werner Syndrome", igniting a wave of interest and research on the disease. [19] During that time, Agatson and Gartner suggested a possible link between Werner's syndrome and cancer. However, it was not until 1966 that there was a general consensus on the autosomal recessive mode of inheritance for the syndrome. By 1981, geneticists had located the WRN gene on chromosome 8, leading to its cloning in 1996. This cloning of the WRN was significant because it revealed the predicted WRN protein was made from a family of DNA helicases. [19] Prior to 1996, Werner syndrome was thought to be a model for accelerated aging. Since the discovery of the gene, it has become clear that the premature aging displayed in Werner syndrome is not the same, on a cellular level, as normal aging. The role of WRN in DNA repair and its exonuclease and helicase activities have been the subject of many studies in recent years. [20]

Since the initial discovery in 1904, several other cases of Werner syndrome have been recorded. Many of these cases have occurred in Japan, where a founder effect has caused a higher incidence rate than in other populations.[ citation needed ] The incidence rate of Werner syndrome in Japan is approximately 1 case per 100 thousand people (1:100,000), a large contrast with the rate of incidence for the rest of the world, which is between 1:1,000,000 and 1:10,000,000. A founder effect is also apparent in Sardinia, where there have been 18 recorded cases of Werner syndrome. [17]

See also

Related Research Articles

<span class="mw-page-title-main">Helicase</span> Class of enzymes to unpack an organisms genes

Helicases are a class of enzymes thought to be vital to all organisms. Their main function is to unpack an organism's genetic material. Helicases are motor proteins that move directionally along a nucleic acid phosphodiester backbone, separating two hybridized nucleic acid strands, using energy from ATP hydrolysis. There are many helicases, representing the great variety of processes in which strand separation must be catalyzed. Approximately 1% of eukaryotic genes code for helicases.

RecQ helicase is a family of helicase enzymes initially found in Escherichia coli that has been shown to be important in genome maintenance. They function through catalyzing the reaction ATP + H2O → ADP + P and thus driving the unwinding of paired DNA and translocating in the 3' to 5' direction. These enzymes can also drive the reaction NTP + H2O → NDP + P to drive the unwinding of either DNA or RNA.

<span class="mw-page-title-main">Xeroderma pigmentosum</span> Medical condition

Xeroderma pigmentosum (XP) is a genetic disorder in which there is a decreased ability to repair DNA damage such as that caused by ultraviolet (UV) light. Symptoms may include a severe sunburn after only a few minutes in the sun, freckling in sun-exposed areas, dry skin and changes in skin pigmentation. Nervous system problems, such as hearing loss, poor coordination, loss of intellectual function and seizures, may also occur. Complications include a high risk of skin cancer, with about half having skin cancer by age 10 without preventative efforts, and cataracts. There may be a higher risk of other cancers such as brain cancers.

<span class="mw-page-title-main">Bloom syndrome</span> Medical condition

Bloom syndrome is a rare autosomal recessive genetic disorder characterized by short stature, predisposition to the development of cancer, and genomic instability. BS is caused by mutations in the BLM gene which is a member of the RecQ DNA helicase family. Mutations in genes encoding other members of this family, namely WRN and RECQL4, are associated with the clinical entities Werner syndrome and Rothmund–Thomson syndrome, respectively. More broadly, Bloom syndrome is a member of a class of clinical entities that are characterized by chromosomal instability, genomic instability, or both and by cancer predisposition.

<span class="mw-page-title-main">Nucleotide excision repair</span> DNA repair mechanism

Nucleotide excision repair is a DNA repair mechanism. DNA damage occurs constantly because of chemicals, radiation and other mutagens. Three excision repair pathways exist to repair single stranded DNA damage: Nucleotide excision repair (NER), base excision repair (BER), and DNA mismatch repair (MMR). While the BER pathway can recognize specific non-bulky lesions in DNA, it can correct only damaged bases that are removed by specific glycosylases. Similarly, the MMR pathway only targets mismatched Watson-Crick base pairs.

<span class="mw-page-title-main">Dyskeratosis congenita</span> Medical condition

Dyskeratosis congenita (DKC), also known as Zinsser-Engman-Cole syndrome, is a rare progressive congenital disorder with a highly variable phenotype. The entity was classically defined by the triad of abnormal skin pigmentation, nail dystrophy, and leukoplakia of the oral mucosa, and MDS/AML, but these components do not always occur. DKC is characterized by short telomeres. Some of the manifestations resemble premature ageing and cognitive impairment can be a feature. The disease initially mainly affects the skin, but a major consequence is progressive bone marrow failure which occurs in over 80%, causing early mortality.

<span class="mw-page-title-main">Werner syndrome helicase</span> Protein-coding gene in the species Homo sapiens

Werner syndrome ATP-dependent helicase, also known as DNA helicase, RecQ-like type 3, is an enzyme that in humans is encoded by the WRN gene. WRN is a member of the RecQ Helicase family. Helicase enzymes generally unwind and separate double-stranded DNA. These activities are necessary before DNA can be copied in preparation for cell division. Helicase enzymes are also critical for making a blueprint of a gene for protein production, a process called transcription. Further evidence suggests that Werner protein plays a critical role in repairing DNA. Overall, this protein helps maintain the structure and integrity of a person's DNA.

A DNA repair-deficiency disorder is a medical condition due to reduced functionality of DNA repair.

Enquiry into the evolution of ageing, or aging, aims to explain why a detrimental process such as ageing would evolve, and why there is so much variability in the lifespans of organisms. The classical theories of evolution suggest that environmental factors, such as predation, accidents, disease, and/or starvation, ensure that most organisms living in natural settings will not live until old age, and so there will be very little pressure to conserve genetic changes that increase longevity. Natural selection will instead strongly favor genes which ensure early maturation and rapid reproduction, and the selection for genetic traits which promote molecular and cellular self-maintenance will decline with age for most organisms.

<span class="mw-page-title-main">ERCC2</span> Mammalian protein found in humans

ERCC2, or XPD is a protein involved in transcription-coupled nucleotide excision repair.

<span class="mw-page-title-main">Rothmund–Thomson syndrome</span> Rare autosomal recessive skin condition.

Rothmund–Thomson syndrome (RTS) is a rare autosomal recessive skin condition.

<span class="mw-page-title-main">Bloom syndrome protein</span> Mammalian protein found in humans

Bloom syndrome protein is a protein that in humans is encoded by the BLM gene and is not expressed in Bloom syndrome.

<span class="mw-page-title-main">POLD1</span> Protein-coding gene in the species Homo sapiens

The gene polymerase delta 1 (POLD1) encodes the large, POLD1/p125, catalytic subunit of the DNA polymerase delta (Polδ) complex. The Polδ enzyme is responsible for synthesizing the lagging strand of DNA, and has also been implicated in some activities at the leading strand. The POLD1/p125 subunit encodes both DNA polymerizing and exonuclease domains, which provide the protein an important second function in proofreading to ensure replication accuracy during DNA synthesis, and in a number of types of replication-linked DNA repair following DNA damage.

<span class="mw-page-title-main">RECQL4</span> Protein-coding gene in the species Homo sapiens

ATP-dependent DNA helicase Q4 is an enzyme that in humans is encoded by the RECQL4 gene.

The DNA damage theory of aging proposes that aging is a consequence of unrepaired accumulation of naturally occurring DNA damage. Damage in this context is a DNA alteration that has an abnormal structure. Although both mitochondrial and nuclear DNA damage can contribute to aging, nuclear DNA is the main subject of this analysis. Nuclear DNA damage can contribute to aging either indirectly or directly.

Synthetic lethality is defined as a type of genetic interaction where the combination of two genetic events results in cell death or death of an organism. Although the foregoing explanation is wider than this, it is common when referring to synthetic lethality to mean the situation arising by virtue of a combination of deficiencies of two or more genes leading to cell death, whereas a deficiency of only one of these genes does not. In a synthetic lethal genetic screen, it is necessary to begin with a mutation that does not result in cell death, although the effect of that mutation could result in a differing phenotype, and then systematically test other mutations at additional loci to determine which, in combination with the first mutation, causes cell death arising by way of deficiency or abolition of expression.

<span class="mw-page-title-main">FANCM</span> Mammalian protein found in Homo sapiens

Fanconi anemia, complementation group M, also known as FANCM is a human gene. It is an emerging target in cancer therapy, in particular cancers with specific genetic deficiencies.

Progeroid syndromes (PS) are a group of rare genetic disorders that mimic physiological aging, making affected individuals appear to be older than they are. The term progeroid syndrome does not necessarily imply progeria, which is a specific type of progeroid syndrome.

<span class="mw-page-title-main">Hereditary cancer syndrome</span> Inherited genetic condition that predisposes a person to cancer

A hereditary cancer syndrome is a genetic disorder in which inherited genetic mutations in one or more genes predispose the affected individuals to the development of cancer and may also cause early onset of these cancers. Hereditary cancer syndromes often show not only a high lifetime risk of developing cancer, but also the development of multiple independent primary tumors.

<span class="mw-page-title-main">Jan Karlseder</span> Austrian molecular biologist

Jan Karlseder is an Austrian molecular biologist, a professor in the Molecular and Cellular Biology Laboratory, the Director of the Paul F. Glenn Center for Biology of Aging Research and the holder of the Donald and Darlene Shiley Chair at the Salk Institute for Biological Studies.

References

  1. ↑ James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' Diseases of the Skin: Clinical Dermatology. (10th ed.). Saunders. ISBN   0-7216-2921-0.
  2. ↑ Norbnop, Phatchara (August 2014). "ZRS 406A>G mutation in patients with tibial hypoplasia, polydactyly and triphalangeal first fingers". Journal of Human Genetics. 59 (8): 467–470. doi: 10.1038/jhg.2014.50 . PMID   24965254. S2CID   21552381.
  3. 1 2 Gray MD, Shen JC, Kamath-Loeb AS, Blank A, Sopher BL, Martin GM, Oshima J, Loeb LA (1997). "The Werner syndrome protein is a DNA helicase". Nat. Genet. 17 (1): 100–3. doi:10.1038/ng0997-100. PMID   9288107. S2CID   20587915.
  4. ↑ synd/892 at Who Named It?
  5. ↑ Werner, Otto (1985). "On Cataract in Conjunction with Scleroderma". Werner's Syndrome and Human Aging. Advances in Experimental Medicine and Biology. Vol. 190. pp. 1–14. doi:10.1007/978-1-4684-7853-2_1. ISBN   978-1-4684-7855-6. PMID   3909762.
  6. 1 2 Hasty P, Campisi J, Hoeijmakers J, van Steeg H, Vijg J (2003). "Aging and genome maintenance: lessons from the mouse?". Science. 299 (5611): 1355–9. doi:10.1126/science.1079161. PMID   12610296. S2CID   840477.
  7. 1 2 3 "Werner syndrome". Genetics Home Reference. Retrieved 18 March 2013.
  8. ↑ Masala MV, Scapaticci S, Olivieri C, Pirodda C, Montesu MA, Cuccuru MA, Pruneddu S, Danesino C, Cerimele D (2007). "Epidemiology and clinical aspects of Werner's syndrome in North Sardinia: description of a cluster". Eur J Dermatol. 17 (3): 213–6. doi:10.1684/ejd.2007.0155 (inactive 31 January 2024). PMID   17478382.{{cite journal}}: CS1 maint: DOI inactive as of January 2024 (link)
  9. 1 2 3 Navarro CL, Cau P, Lévy N (2006). "Molecular bases of progeroid syndromes". Hum. Mol. Genet. 15 Spec No 2: R151–61. doi: 10.1093/hmg/ddl214 . PMID   16987878.
  10. 1 2 Epstein CJ, Martin GM, Schultz AL, Motulsky AG (1966). "Werner's syndrome a review of its symptomatology, natural history, pathologic features, genetics and relationship to the natural aging process". Medicine (Baltimore). 45 (3): 177–221. doi: 10.1097/00005792-196605000-00001 . PMID   5327241.
  11. 1 2 Oshima J, Martin GM, Hisama FM (February 2012) [1993–]. "Werner Syndrome". In Pagon RA, Bird TD, Dolan CR, et al. (eds.). GeneReviews. Seattle WA: University of Washington, Seattle. PMID   20301687. NBK1514.
  12. 1 2 Oshima J, Martin GM, Hisama FM. Werner Syndrome. 2002 Dec 2 [Updated 2012 Dec 13]. In: Pagon RA, Bird TD, Dolan CR, et al., editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-. Available from:https://www.ncbi.nlm.nih.gov/books/NBK1514/
  13. ↑ Goto M, Miller RW, Ishikawa Y, Sugano H (1996). "Excess of rare cancers in Werner syndrome (adult progeria)". Cancer Epidemiol. Biomarkers Prev. 5 (4): 239–46. PMID   8722214.
  14. ↑ Kyng KJ, May A, Kølvraa S, Bohr VA (2003). "Gene expression profiling in Werner syndrome closely resembles that of normal aging". Proc. Natl. Acad. Sci. U.S.A. 100 (21): 12259–64. Bibcode:2003PNAS..10012259K. doi: 10.1073/pnas.2130723100 . PMC   218746 . PMID   14527998.
  15. ↑ Kyng K, Croteau DL, Bohr VA (2009). "Werner syndrome resembles normal aging". Cell Cycle. 8 (15): 2319–2323. doi:10.4161/cc.8.15.9148. PMC   4172458 . PMID   19633413.
  16. 1 2 3 "Genetics Home Reference". US National Library of Medicine.
  17. 1 2 3 4 5 Coppedè, Fabio (August 2013). "The epidemiology of premature aging and associated comorbidities". Clinical Interventions in Aging. 8: 1023–32. doi: 10.2147/CIA.S37213 . PMC   3760297 . PMID   24019745.
  18. 1 2 3 4 5 6 7 Monnat RJ (2010). "Human RECQ helicases: roles in DNA metabolism, mutagenesis and cancer biology". Semin. Cancer Biol. 20 (5): 329–39. doi:10.1016/j.semcancer.2010.10.002. PMC   3040982 . PMID   20934517.
  19. 1 2 3 4 5 6 7 8 Goto, Makoto (2004). Clinical Aspects of Werner's Syndrome: Its Natural History and the Genetics of the Disease. Eurekah.com and Kluwer Academic / Plenum Publishing. p. 1.
  20. 1 2 3 4 Chen L, Huang S, Lee L, Davalos A, Schiestl RH, Campisi J, Oshima J (2003). "WRN, the protein deficient in Werner syndrome, plays a critical structural role in optimizing DNA repair". Aging Cell. 2 (4): 191–9. doi:10.1046/j.1474-9728.2003.00052.x. PMID   12934712. S2CID   25838286.
  21. ↑ Rossi ML, Ghosh AK, Bohr VA (March 2010). "Roles of Werner syndrome protein in protection of genome integrity". DNA Repair (Amst.). 9 (3): 331–44. doi:10.1016/j.dnarep.2009.12.011. PMC   2827637 . PMID   20075015.
  22. ↑ Goto M, Rubenstein M, Weber J, Woods K, Drayna D (Feb 1992). "Genetic linkage of Werner's syndrome to five markers on chromosome 8". Nature. 355 (6362): 735–8. Bibcode:1992Natur.355..735G. doi:10.1038/355735a0. PMID   1741060. S2CID   4241791.
  23. ↑ Bernstein KA, Gangloff S, Rothstein R (2010). "The RecQ DNA helicases in DNA repair". Annu. Rev. Genet. 44: 393–417. doi:10.1146/annurev-genet-102209-163602. PMC   4038414 . PMID   21047263.
  24. ↑ Chen L, Oshima J (2002). "Werner Syndrome". J. Biomed. Biotechnol. 2 (2): 46–54. doi: 10.1155/S1110724302201011 . PMC   153784 . PMID   12488583.
  25. ↑ Pichierri P, Ammazzalorso F, Bignami M, Franchitto A (March 2011). "The Werner syndrome protein: linking the replication checkpoint response to genome stability". Aging. 3 (3): 311–8. doi:10.18632/aging.100293. PMC   3091524 . PMID   21389352.
  26. ↑ Harris CC (1996). "Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies". J. Natl. Cancer Inst. 88 (20): 1442–55. doi: 10.1093/jnci/88.20.1442 . PMID   8841019.
  27. 1 2 Opresko PL, Cheng WH, von Kobbe C, Harrigan JA, Bohr VA (2003). "Werner syndrome and the function of the Werner protein; what they can teach us about the molecular aging process". Carcinogenesis. 24 (5): 791–802. doi: 10.1093/carcin/bgg034 . PMID   12771022.
  28. ↑ Kamath-Loeb AS, Zavala-van Rankin DG, Flores-Morales J, Emond MJ, Sidorova JM; et al. (2017). "Homozygosity for the WRN helicase-inactivating variant, R834C, does not confer a Werner syndrome clinical phenotype". Sci. Rep. 7: 44081. Bibcode:2017NatSR...744081K. doi:10.1038/srep44081. PMC   5343477 . PMID   28276523.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  29. 1 2 Thompson LH, Schild D (2002). "Recombinational DNA repair and human disease". Mutat. Res. 509 (1–2): 49–78. doi:10.1016/s0027-5107(02)00224-5. PMID   12427531.
  30. 1 2 Kusumoto R, Dawut L, Marchetti C, Wan Lee J, Vindigni A, Ramsden D, Bohr VA (2008). "Werner protein cooperates with the XRCC4-DNA ligase IV complex in end-processing". Biochemistry. 47 (28): 7548–56. doi:10.1021/bi702325t. PMC   2572716 . PMID   18558713.
  31. ↑ Otterlei M, Bruheim P, Ahn B, Bussen W, Karmakar P, Baynton K, Bohr VA (2006). "Werner syndrome protein participates in a complex with RAD51, RAD54, RAD54B and ATR in response to ICL-induced replication arrest" (PDF). J. Cell Sci. 119 (Pt 24): 5137–46. doi:10.1242/jcs.03291. PMID   17118963. S2CID   28357205.
  32. ↑ Harrigan JA, Wilson DM, Prasad R, Opresko PL, Beck G, May A, Wilson SH, Bohr VA (2006). "The Werner syndrome protein operates in base excision repair and cooperates with DNA polymerase beta". Nucleic Acids Res. 34 (2): 745–54. doi:10.1093/nar/gkj475. PMC   1356534 . PMID   16449207.
  33. 1 2 Huang S, Lee L, Hanson NB, Lenaerts C, Hoehn H, Poot M, Rubin CD, Chen DF, Yang CC, Juch H, Dorn T, Spiegel R, Oral EA, Abid M, Battisti C, Lucci-Cordisco E, Neri G, Steed EH, Kidd A, Isley W, Showalter D, Vittone JL, Konstantinow A, Ring J, Meyer P, Wenger SL, von Herbay A, Wollina U, Schuelke M, Huizenga CR, Leistritz DF, Martin GM, Mian IS, Oshima J (2006). "The spectrum of WRN mutations in Werner syndrome patients". Hum. Mutat. 27 (6): 558–67. doi:10.1002/humu.20337. PMC   1868417 . PMID   16673358.
  34. ↑ Spillare EA, Robles AI, Wang XW, Shen JC, Yu CE, Schellenberg GD, Harris CC (1999). "p53-mediated apoptosis is attenuated in Werner syndrome cells". Genes Dev. 13 (11): 1355–60. doi:10.1101/gad.13.11.1355. PMC   316776 . PMID   10364153.
  35. ↑ Martin GM, Sprague CA, Epstein CJ (1970). "Replicative life-span of cultivated human cells. Effects of donor's age, tissue, and genotype". Lab. Invest. 23 (1): 86–92. PMID   5431223.
  36. ↑ Salk D, Au K, Hoehn H, Martin GM (1981). "Cytogenetics of Werner's syndrome cultured skin fibroblasts: variegated translocation mosaicism". Cytogenet. Cell Genet. 30 (2): 92–107. doi:10.1159/000131596. PMID   7273860.
  37. ↑ Fukuchi K, Martin GM, Monnat RJ (1989). "Mutator phenotype of Werner syndrome is characterized by extensive deletions". Proc. Natl. Acad. Sci. U.S.A. 86 (15): 5893–7. Bibcode:1989PNAS...86.5893F. doi: 10.1073/pnas.86.15.5893 . PMC   297737 . PMID   2762303.
  38. 1 2 Crabbe L, Jauch A, Naeger CM, Holtgreve-Grez H, Karlseder J (2007). "Telomere dysfunction as a cause of genomic instability in Werner syndrome". Proc. Natl. Acad. Sci. U.S.A. 104 (7): 2205–10. Bibcode:2007PNAS..104.2205C. doi: 10.1073/pnas.0609410104 . JSTOR   25426449. PMC   1794219 . PMID   17284601.
  39. ↑ Chan SR, Blackburn EH (2004). "Telomeres and telomerase". Philos. Trans. R. Soc. Lond. B Biol. Sci. 359 (1441): 109–21. doi:10.1098/rstb.2003.1370. PMC   1693310 . PMID   15065663.
  40. ↑ Multani AS, Chang S (2006). "WRN at telomeres: implications for aging and cancer". J. Cell Sci. 120 (Pt 5): 713–21. doi:10.1242/jcs.03397. PMID   17314245. S2CID   6734884.
  41. 1 2 Szekely AM, Bleichert F, Nümann A, Van Komen S, Manasanch E, Ben Nasr A, Canaan A, Weissman SM (2005). "Werner protein protects nonproliferating cells from oxidative DNA damage". Mol. Cell. Biol. 25 (23): 10492–506. doi:10.1128/MCB.25.23.10492-10506.2005. PMC   1291253 . PMID   16287861.
  42. ↑ "Werner's Syndrome: Treatments". Progeria Information Database. Retrieved April 12, 2014.
  43. ↑ Davis T, Kipling D (2006). "Werner Syndrome as an example of inflamm-aging: possible therapeutic opportunities for a progeroid syndrome?". Rejuvenation Res. 9 (3): 402–7. doi:10.1089/rej.2006.9.402. PMID   16859481.
  44. ↑ Massip L, Garand C, Paquet ER, Cogger VC, O'Reilly JN, Tworek L, Hatherell A, Taylor CG, Thorin E, Zahradka P, Le Couteur DG, Lebel M (2009-09-09). "Vitamin C restores healthy aging in a mouse model for Werner syndrome". FASEB J. 24 (1): 158–72. doi: 10.1096/fj.09-137133 . PMC   3712979 . PMID   19741171.
  45. ↑ Coppedè F (August 5, 2013). "The epidemiology of premature aging and associated comorbidities". Clin Interv Aging. 8: 1023–32. doi: 10.2147/CIA.S37213 . PMC   3760297 . PMID   24019745.

This article incorporates public domain text from The U.S. National Library of Medicine

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.